Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive multiple sclerosis by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
Ocrelizumab is currently being assessed for drug licensing by the EMA (European Medicines Agency) for both relapsing remitting and primary progressive MS. It will then be appraised for cost and effectiveness as an NHS treatment for both types of MS. If these steps are successful ocrelizumab could be available on the NHS by 2018 at the earliest. The FDA decision does not affect the European assessment.
Pam Macfarlane, Chief Executive of the MS Trust commented:
"This is an encouraging step forward for people with PPMS in the USA. Though the UK is part of a separate licensing process in Europe and there is still a long way to go, the FDA decision is a cause for optimism. The MS Trust will keep watching how things are developing here and provide updates when we can. We are well aware how important this new medicine could be for people with PPMS."
Ocrelizumab is taken as an intravenous infusion (drip) every six months. It reduces the number of B cells, a type of white blood cell, or lymphocyte thought to be involved in the abnormal immune response that attacks the myelin coating of nerve cells.
- In primary progressive MS, people taking ocrelizumab were 24% less likely to have an increase in their disability than those taking placebo
- In relapsing remitting MS, ocrelizumab reduced relapse rates by approximately 50% compared to beta interferon
- Infusion-related reactions, chest infections and herpes (oral herpes and shingles) were more frequent in those taking ocrelizumab
- Neoplasms (abnormal growth of tissues which can be benign or malignant), including several cases of breast cancer, were reported more frequently in those taking ocrelizumab
The impact of Covid-19 on the mental health of people with MS
5 May 2021 - 00:00
In April 2020 we shared a research study with members of our Facebook group. The study was conducted by the University of Reading and looked at the impact of Covid-19 on people with multiple sclerosis. In this blog we take a look at the findings.
"Starting a podcast in lockdown helped us take ownership of the situation"
23 Apr 2021 - 00:00
Comedian, Jeanette and Poet, Lytisha, talk about how creating their own podcast, about life with MS, led to lots of laughs, feelings of empowerment and a sense of community during lockdown.
Twelve year old Lacey hasn't been able to hug her dad for a year
23 Apr 2021 - 00:00
Before lockdown Lacey visited her dad every other weekend, but Covid restrictions have meant she’s not been able to visit her dad in his care home and give him a hug since March 2020.